cas 20028-53-9|| where to buy 2-Amino-5-chlorobenzaldehyde

Nom du produit:2-Amino-5-chlorobenzaldehyde

IUPAC Name:2-amino-5-chlorobenzaldehyde

Unité d'emballage	Stock disponible	Prix($)
CM251042-5g	in stock	ƩǠǺ
CM251042-10g	in stock	ǺŸȤ
CM251042-25g	in stock	ǠşǺ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 20028-53-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:20028-53-9; Formule moléculaire:C7H6ClNO; Point de fusion:-; Code SMILES:NC1=CC=C(Cl)C=C1C=O; Densité:

: Numéro de catalogue:CM251042; Poids moléculaire:155.58; Point d'ébullition:288.1°C at 760 mmHg; N° Mdl:MFCD02093936; Stockage:Keep in dark place, inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Olutasidenib; Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.